Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cyclerion Therapeutics Inc CYCN

Healthcare Biotechnology
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing treatments for serious diseases. The Company’s portfolio includes novel soluble guanylate cyclase (sGC) stimulators, namely praliciguat and olinciguat, as well as multiple research stage molecules. Praliciguat is a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. Olinciguat is a vascular sGC stimulator that the Company intends to out-license for cardiovascular diseases. The Company operates through the human therapeutics segment. The Company is focused on identifying non-sGC stimulator assets within the central nervous system (CNS) therapeutic area to build a new portfolio. The Company is also evaluating other activities aimed at enhancing shareholder value, which potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments.


NDAQ:CYCN - Post by User

Cyclerion Therapeutics Inc
<< Previous
 Bullboard Posts
User Avatar Image
(4)
•••
Post by AviseAnalyticson Nov 12, 2021 7:05am
98 Views
Post# 34118397

5 STOCKS FOR YOUR INVESTMENT WATCHLIST!

5 STOCKS FOR YOUR INVESTMENT WATCHLIST!

5 STOCKS FOR YOUR INVESTMENT WATCHLIST!

 

CYCN COGT QIPT CHS POLY

https://www.aviseanalytics.com/5-stocks-for-your-investment-watchlist/

 

Technology Industry has been focused on minimizing the impact of COVID-19 and marching ahead with its innovations and breakthroughs, be it critical security systems, innovative marketing solutions or cutting-edge data analytics and search technology.

 

We take a look at some tech companies that are impervious to the scare and offer a very attractive upside in the long run.

https://www.aviseanalytics.com/5-stocks-for-your-investment-watchlist/

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities